The Health Subcommittee of the House of Representatives’ Energy and Commerce Committee will consider H.R. 8000 on March 26, a bill that would place 7-hydroxymitragynine—an opioid-like compound derived from the kratom plant—on Schedule I of the Controlled Substances Act. This legislative move comes ahead of an executive branch review for a temporary emergency scheduling order and bypasses the standard eight-factor analysis typically required in such cases.
The decision to advance this bill is seen as an effort by Congress to address concerns about public safety, given claims regarding the addictive potential of 7-hydroxymitragynine (also known as 7-OH) and its possible role in overdoses. The substance interacts with brain receptors similarly to opioids like morphine but activates them differently, and it remains commercially available at gas stations, smoke shops, and convenience stores.
Supporters of more research argue that moving quickly to schedule 7-OH could impede scientific study into both its risks and potential therapeutic uses. Under current law, substances placed on Schedule I are considered to have no accepted medical use and a high potential for abuse. This classification makes it difficult for researchers to access these substances due to regulatory hurdles and increased costs.
The article points out that most current safety claims are based on limited data despite widespread use, highlighting the need for further research before making permanent regulatory decisions. There is also concern that removing legal access could drive individuals who rely on these products for pain or opioid use disorder treatment toward illicit markets, increasing their risk.
Examples from previous drug rescheduling efforts suggest that once a substance is placed in Schedule I, reversing or adjusting its status can be slow and rare—even when new evidence emerges about medical benefits or reduced harm. The article concludes by emphasizing the importance of following established scientific procedures before enacting new drug controls.
